Testimonial by Mathieu Nadeau-Vallée!

Mathieu Nadeau-Vallée

Contributed Article: “Preterm Birth and Neonatal Injuries: Importance of Interleukin-1 and Potential of Interleukin-1 Receptor Antagonists

SMi EVENT – 9th Annual RNA Therapeutics Conference!

SMi Group announces the 9th Annual RNA Therapeutics Conference in London on February 21st – 22nd 2018.

RNA t[

As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies has increasingly focused towards RNA therapeutics, such that by 2020, the RNA Therapeutics Market is predicted to attain $1.2 billion.http://bit.ly/2xtvCH1

One of the main challenges in RNA Therapeutics continues to be bridging the gap between in-vivo and in-vitro models, hear key case studies on the development on the latest delivery systems and evaluate with key industry leaders the lessons they’ve learnt whilst developing an RNA therapeutic.  The full speaker line-up and conference agenda is available at http://www.therapeutics-rna.com/bnths 

For more information visit the website at http://www.therapeutics-rna.com/bnths or contact the team on email: psolanki@smi-online.co.uk or call +44 (0) 207 827 6012

Journal: Current Pharmaceutical Design

EBook: Frontiers in RNAi


Guido Rubboli

Contributed Article: “Management of Antiepileptic Treatment After Epilepsy Surgery – Practices And Problems


MOST ACCESSED ARTICLE – Targeted Nanoparticles for the Treatment of Alzheimer’s Disease – Current Pharmaceutical Design

Journal: Current Pharmaceutical Design

Author(s): Rafael Martín-Rapun, Laura De Matteis, Alfredo Ambrosone, Sonia Garcia-Embid, Lucia Gutierrez, Jesus M. de la Fuente


Background: Alzheimer’s disease (AD) has a dramatic impact on society. The therapeutic targets are located in the central nervous system (CNS), which limits the efficacy of drugs systemically administered: the blood-brain barrier (BBB) selectively allows the permeation of just a few kinds of molecules from the systemic circulation to the CNS. On the other hand, local administration routes to CNS are highly invasive.

Methods: In this article, we have reviewed therapeutic approaches against AD, which are based on nanoparticles targeted to the brain and to the pathological hallmarks of the disease. The existing literature has been classified according to the AD feature that is addressed.

Results: Nanoparticles have been used for the targeted delivery of drugs aiming to reduce the AD symptoms or to reverse the course of the disease. For this task the multivalency of nanoparticles has allowed their functionalization with several kinds of targeting groups, to cross the BBB and to target the place of treatment. With this approach an increased drug bioavailability has been achieved in the CNS using intravenous administration in place of more invasive administration routes. Additionally, nanoparticles have also been used in the development of vaccines and therapeutic formulations for intranasal administration.
Conclusion: Targeted nanoparticles have been proved useful to enhance the performance of therapies against AD in animal models. A better understanding of AD mechanisms will help the successful application of targeted nanoparticles for combined therapies.

To access the article, please visit: http://www.eurekaselect.com/148709

Highlighted Article – Update on Pharmacological Treatment of Progressive Myoclonus Epilepsies – Current Pharmaceutical Design

cpd- Articles_23-46-Edoardo Ferlazzo

To access this article, please visit: http://www.eurekaselect.com/154784

Testimonial by Liliya Vasileva!

Liliya Vasileva.jpg

Contributed Article: “Current And Emerging Strategies in Osteoporosis Management

Testimonial by Yu-Long Lan!

Yu-Long Lan

Contributed Article: “Aquaporin 4 in Astrocytes Is A Target For Therapy In Alzheimer’s Disease

Recently Published Issues – Bentham Science Journals

Current Analytical Chemistry 13, Issue 5

Current Pharmaceutical Design 23, Issue 21

Current Organic Chemistry 21, Issue 17

Current Protein & Peptide Science 18, Issue 11

Recent Patents on Anti-Cancer Drug Discovery 12, Issue 3

Current Cancer Therapy Reviews 13, Issue 1


Podcast: Targeting Human Astrocytes’ Calcium-sensing Receptors for Treatment of Alzheimer’s Disease

Author(s): Ikuko Miyazaki, Masato Asanuma.

For article details, visit: http://www.eurekaselect.com/154088

Subscribe our YouTube channelhttp://bit.ly/1lr0czy

Highlighted Article – Therapeutic Strategy of Targeting Astrocytes for Neuroprotection in Parkinson’s Disease – Current Pharmaceutical Design

CPD-Articles_23-46-Ikuko Miyazaki

To access this article, please visit: http://www.eurekaselect.com/154088